4D Molecular Therapeutics, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. Clinical-stage genetic-medicines company developing targeted AAV-vector therapies. This unaudited report covers the three months ended March 31, 2024, compared with Q1 2023. Its clinical pipeline includes 4D-150, 4D-710, 4D-310, 4D-125 and 4D-110; 4D-175 and 4D-725 are in preclinical development. No product candidates are approved, and the company has no product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Collaboration and license revenue | $0.028 million | $0.298 million |
| Research and development expense | $27.870 million | $22.412 million |
| General and administrative expense | $10.294 million | $7.992 million |
| Total operating expenses | $38.164 million | $30.404 million |
| Operating loss | $38.136 million | $30.106 million |
| Interest income | $5.745 million | $1.443 million |
| Net loss | $32.401 million; $0.66 per share | $28.682 million; $0.88 per share |
| Net cash used in operating activities | $29.088 million | $27.906 million |
At March 31, 2024, cash and cash equivalents were $275.6 million and marketable securities totaled $313.3 million, or $588.9 million combined. Total assets were $629.9 million, current assets $535.6 million and current liabilities $16.4 million. The company reported no borrowings; operating lease liabilities were $14.2 million. Accumulated deficit was $447.7 million. Management believes available cash, cash equivalents and marketable securities will fund planned operations for at least one year from the financial-statement issuance date.
Material changes versus Q1 2023
- Revenue fell 91%, primarily because the uniQure performance obligation was completed in 2023; Q1 2024 revenue was mainly immaterial Cystic Fibrosis Foundation (CFF) revenue.
- R&D expense rose 24%, mainly from increased clinical-trial activity, particularly 4D-150, and higher personnel costs. G&A expense rose 29%, reflecting personnel and other operating costs.
- Net loss increased by $3.7 million, while loss per share narrowed from $0.88 to $0.66, reflecting a higher weighted-average share count.
- Interest income increased as cash and investment balances and market yields rose.
- A February 2024 public offering and March underwriter option exercise generated substantial funding. The company issued common shares and pre-funded warrants; common shares outstanding were 51.2 million at quarter-end. The warrants cover a further 3.6 million shares at a $0.0001 exercise price.
Outlook, risks and notable items
- Management expects continuing operating losses and negative operating cash flows, with R&D and G&A spending expected to increase. No specific earnings, revenue or trial-timing guidance is provided.
- The company says it will need substantial additional capital over time and has no committed external funding source. Financing may dilute shareholders or require debt, partnerships, licensing or reduced development activity. Available funds could be used sooner than expected.
- Key risks include clinical and regulatory uncertainty for novel gene therapies; safety, manufacturing and supply constraints; trial enrollment and execution; competition; intellectual-property protection; and dependence on third parties. Actual development costs and timing are uncertain.
- The CFF agreement includes potential commercialization, royalty and change-of-control payments. Its change-of-control embedded derivative was valued at $0.4 million; the filing describes potential change-of-control payments ranging up to $18.9 million under specified assumptions. CFF deferred revenue was $1.3 million.
- A January 2024 warehouse lease is expected to commence in August 2024 and entails approximately $1.5 million of future minimum payments. No lease asset or liability had been recorded at quarter-end.
- In March, the company entered a research and option agreement with Reignite Therapeutics, founded by CEO David Kirn. No Q1 expense was incurred; the company may fund research up to $1.5 million per year and pay up to $3.0 million to exercise options for capsids.
- No material legal proceedings were outstanding. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether clinical data and trial progress for 4D-150 and other candidates support the expected development plans, and whether any safety, enrollment or manufacturing issues emerge.
- Cash burn, investment maturities and management’s basis for the stated runway, including the timing and terms of any future financing.
- The fully diluted share count and potential dilution from pre-funded warrants, options, RSUs and reserved equity-plan shares.
- Potential CFF obligations, including milestone, royalty and change-of-control payments, and the related assumptions underlying the derivative valuation.
- The terms, governance and future spending under the related-party Reignite agreement.